Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Success of chemotherapy and a liver transplant in a pediatric patient with hepatic angiosarcoma: A case report.

Pilbeam K, Eidenschink B, Sulciner M, Luquette M, Neglia J, Chinnakotla S.

Pediatr Transplant. 2019 Jun;23(4):e13410. doi: 10.1111/petr.13410. Epub 2019 Apr 23.

PMID:
31012199
2.

Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors.

Pilbeam K, Wang H, Taras E, Bergerson RJ, Ettestad B, DeFor T, Borgatti A, Vallera DA, Verneris MR.

Oncotarget. 2017 Sep 23;9(15):11938-11947. doi: 10.18632/oncotarget.21187. eCollection 2018 Feb 23.

3.

Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR.

Borgatti A, Koopmeiners JS, Sarver AL, Winter AL, Stuebner K, Todhunter D, Rizzardi AE, Henriksen JC, Schmechel S, Forster CL, Kim JH, Froelich J, Walz J, Henson MS, Breen M, Lindblad-Toh K, Oh F, Pilbeam K, Modiano JF, Vallera DA.

Mol Cancer Ther. 2017 May;16(5):956-965. doi: 10.1158/1535-7163.MCT-16-0637. Epub 2017 Feb 13.

4.

Pediatric multiple myeloma.

Pilbeam KL, Lund TC.

Blood. 2017 Jan 19;129(3):395. doi: 10.1182/blood-2016-09-741322. No abstract available.

PMID:
28104677
5.

The ontogeny and fate of NK cells marked by permanent DNA rearrangements.

Pilbeam K, Basse P, Brossay L, Vujanovic N, Gerstein R, Vallejo AN, Borghesi L.

J Immunol. 2008 Feb 1;180(3):1432-41.

Supplemental Content

Loading ...
Support Center